circRNA Dysfunction Restoration Therapy <table class="infobox infobox-therapeutic">
...
circRNA Dysfunction Restoration Therapy <table class="infobox infobox-therapeutic">
Overview
Mermaid diagram (expand to render)
This therapeutic concept targets the restoration of circular RNA (circRNA) function in neurodegenerative diseases. CircRNAs are abundant in the brain, highly stable, and play critical roles in synaptic function, protein translation, and gene regulation. Their dysregulation contributes to amyloid metabolism, [tau](/proteins/tau) pathology, [alpha-synuclein](/proteins/alpha-synuclein) regulation, and synaptic dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
Therapeutic Rationale
Disease Context CircRNAs are covalently closed loop structures lacking 5' caps and 3' poly(A) tails, conferring high stability in brain tissue. In neurodegeneration:
Alzheimer's Disease : Global downregulation of circRNAs in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex); circAPP upregulation contributes to amyloid pathology; circHIPK2 and circMAPT affect tau phosphorylation and synaptic plasticity[@circular2023][@synaptic2023].Parkinson's Disease : circSNCA upregulation sequesters miR-7 and miR-153, leading to increased alpha-synuclein production; mitochondrial dysfunction-associated circRNAs are differentially expressed[@circsncamediated2023].ALS : circRNAs derived from [TDP-43](/mechanisms/tdp-43-proteinopathy)-regulated genes show altered expression; loss of TDP-43 function affects circRNA biogenesis, creating a feed-forward pathological loop[@tdp2024].Mechanism of Action The therapeutic approach restores circRNA function through:
ASO-mediated circRNA restoration : Antisense oligonucleotides designed to promote back-splicing of specific neuroprotective circRNAs[5]MiRNA sponge replacement : Engineered circRNA mimics that restore miRNA sequestration capacityGene therapy delivery : AAV vectors carrying circRNA expression cassettes[6]
10-Dimension Scoring Total Score: 71/100
Target Indications
Development Pathway
Preclinical (Years 1-2)
Target Identification : Prioritize circRNAs with strongest disease-correlation (circMAPT, circSNCA, circHIPK2)ASO Design : Develop back-splicing modulators using high-throughput screeningIn vitro Validation : Test in iPSC-derived neurons from AD/PD patientsAnimal Studies : Evaluate delivery, efficacy, and toxicity in mouse models
Clinical (Years 3-5)
Phase 1 : Safety in healthy volunteers; biomarker correlationPhase 2 : Dose-finding in early-stage AD/PD patientsPhase 3 : Efficacy endpoints with biomarker readouts
Competitive Landscape
Risks and Mitigation
Regulatory Considerations
ASO pathway established (e.g., Spinraza, Teplizumab)
Biomarker-driven development possible under FDA/EMA accelerated pathways
Orphan drug designation potential for rare ALS/FTD subtypes
See Also
[Circular RNA Dysfunction in Neurodegeneration](/mechanisms/circular-rna-dysfunction-neurodegeneration)
[RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
[Synaptic Dysfunction in Neurodegeneration](/mechanisms/synaptic-dysfunction)
[Non-Coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
[SNCA Gene](/genes/snca)
[APP Gene](/genes/app)
[MAPT Gene](/genes/mapt)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Actionable Next Steps
Lab Experiments
Clinical Protocol [^
I### Phase 1: Target Validation & ASO Development (Mon- Budget : $3.5-5.5M
**Mile - Month 6: Complete circRNA profiling in 50 patient iPSC lines (AD/P - Month 9: Identify 3 l - Month 12: Design - Month
Phase 2: Preclinical Development (Months 15-30)
Budget : $10-18MMilestones :Month 21: IND-enabling studies complete
Month 24: Pre-IND meeting with FDA; biomarker validation
Month 27: IND filing
Month 30: Phase 1 ready
Phase 3: Clinical Development (Months 30-54)
Budget : $40-65MMilestones :Month 34: Phase 1a SAD complete (24 subjects)
Month 40: Phase 1b MAD complete (48 subjects), dose selection
Month 46: Phase 2 initiated (150 subjects)
Month 54: Phase 2 complete; efficacy signal assessment
Total Program Cost: $53.5-88.5M over 54 months
Risk-Adjusted Scenarios
Key Decision Gates
Academic & Industry Partners
Academic : Dr. Sebastian Kadener (Harvard) - circRNA biogenesis; Dr. Jan L. van Deutekom (Leiden) - ASO designIndustry : Ionis Pharmaceuticals, Roche CNS, Circio HoldingsFoundations : Alzheimer's Association, Michael J. Fox Foundation, ALS AssociationRelated Pages
Circular RN- RNA Metab- Synaptic Dysfunction in Neurodegeneration
Non-Coding RNAs in Neurodegeneration
[SNCA Gene](/genes/snca)
APP Gene
[MAPT Gene](/genes/mapt)
References
[Unknown, Circular RNAs in Alzheimer's Disease: From Bench to Bedside (2023) (2023)](https://doi.org/10.1007/s12035-023-03456-w)
[Unknown, Synaptic Circular RNAs: Implications for Neurodegenerative Diseases (2023) (2023)](https://doi.org/10.1007/s00401-023-02568-4)
[Unknown, circSNCA-mediated Pathogenesis in Parkinson's Disease (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105890)
[Unknown, TDP-43 and Circular RNAs in Amyotrophic Lateral Sclerosis (2024) (2024)](https://doi.org/10.1093/brain/awaa123)
[Unknown, CircRNA-based Therapeutics for Neurological Disorders (2024) (2024)](https://doi.org/10.1038/s41582-024-00890-8)
[Unknown, Biogenesis and Function of Circular RNAs in the Mammalian Brain (2022) (2022)](https://doi.org/10.1038/s41583-022-00567-8) Show full description